Key points are not available for this paper at this time.
To the Editor: Sirolimus is a new, highly potent immunosuppressive drug1,2 that was recently licensed in the United States and is currently being evaluated in phase 3 clinical trials in Europe. The...
Morélon et al. (Thu,) studied this question.